| Literature DB >> 27081294 |
Meng Gao1, Su Zhang2, Chunjie Liu3, Yayun Qin1, Stephen Archacki4, Ling Jin5, Yong Wang6, Fei Liu1, Jiaxiang Chen1, Ying Liu1, Jiuxiang Wang1, Mi Huang1, Shengjie Liao1, Zhaohui Tang1, An Yuan Guo3, Fagang Jiang5, Mugen Liu1.
Abstract
PURPOSE: To investigate the genetic basis and its relationship to the clinical manifestations in a four generation Chinese family with autosomal dominant retinitis pigmentosa.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27081294 PMCID: PMC4812529
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
Figure 1Pedigree structure of the Chinese family with autosomal dominant retinitis pigmentosa (adRP). The squares and cycles represent males and females respectively. Filled symbols represent affected patients while the empty symbols represent unaffected individuals. Wild-type (−/−), heterozygous (+/−) carrier of the mutation. The proband is indicated by arrow. The symbols with a question mark represent the individuals with unknown phenotype.
Clinical features of the participants in this study.
| ID | Age (yrs) | Sex | Disease status | Age at onset (yrs) | Visual acuity | Fundus appearance | Color vision | ERG | OCT | Visual field |
|---|---|---|---|---|---|---|---|---|---|---|
| II:2 | 68 | M | Aff | 30s | <0.1/0.2 | PD, AA, MD,
POD | BB | Diminished | Thinning PL and RPE;
Disrupted choroid | visual field loss |
| II:3 | 63 | M | Aff | 30s | <0.1/0.1 | PD, AA, MD,
POD | BB | Diminished | Thinning PL and RPE;
Disrupted choroid | visual field loss |
| III:2 | 48 | F | Aff | 20s | <0.1/0.1 | PD, AA, MD,
POD | BB | Not examined | Thinning PL and RPE;
Disrupted choroid | Not examined |
| III:3 | 43 | F | Un | - | Not examined | No obvious RP symptoms | Normal | Normal | Not examined | Normal |
| III:4 | 40 | M | Aff | 20s | <0.1/0.1 | PD, AA, MD,
POD | BB | Not examined | Thinning PL and RPE;
Disrupted choroid | visual field loss |
| III:5 | 39 | F | Un | - | Not examined | No obvious RP symptoms | Normal | Normal | Normal | Not examined |
| III:7 | 34 | M | Aff | 10s | LP | PD, AA, MD,
POD | BB | Diminished | Thinning PL and RPE;
Disrupted choroid | visual field loss |
| III:10 | 26 | M | Un | - | Not examined | No obvious RP symptoms | Normal | Normal | Normal | Normal |
| III:11 | 21 | F | Aff | 20s | Not examined | No obvious RP symptoms | Normal | Diminished rod response, normal cone response | Normal | Normal |
| III:15 | 31 | F | Aff | 20s | <0.2/0.2 | PD, AA, MD, POD | BB | Not examined | Thinning PL and RPE; Disrupted choroid | Not examined |
Abbreviations: M: male; F: female; Aff: affected; Un: unaffected; ERG: electroretinography; LP: light permission; OCT: optical coherence tomography; PD: pigment deposition; AA: attenuated retinal arterioles; MD: macular degeneration; POD: pale optic discs; BB: blue color blindness; PL: photoreceptor layer; RPE: retinal pigment epithelium
Figure 2Fundus photography and OCT test of normal and affected member of this pedigree. Fundus photograph of the normal individual III:10 (A) and the patient II:3 (B) revealed that the patients had typical RP symptoms including attenuated retinal arterioles, peripheral intraretinal pigment deposits in a bone-spicule configuration, degenerated macula and diffused mottling of retinal pigmented epithelium. Optical coherence tomography (OCT) images of the normal individual III:10 (C) and the patient II:3 (D) showed that the patient had marked thinning and disruption of the photoreceptor layer and the retinitis pigment epithelium.
Six candidate mutations detected from the whole exome sequencing.
| Gene | Gene Bank ID | Exon | Nucleotide change | Amino acid change |
|---|---|---|---|---|
| NRL | NM_006177 | 2 | c.146C>T | p.P49L |
| TRIM32 | NM_012210 | 2 | c.284T>C | p.V95A |
| CERKL | NM_ 201548 | 2 | c.346A>G | p.T116A |
| STL2 | NM_001854 | 33 | c.2645G>A | p.R882H |
| TREX1 | NM_016381 | 1 | c.161C>A | p.P54Q |
| BEST1 | NM_001139443 | 9 | c.1687C>T | p.R563C |
Primers used for the identification of the pathogenic mutation in this family.
| Primers | Forward | Reverse | Product (bp) |
|---|---|---|---|
| NRL | CAGGGCACTTGGGCTTTGAG | CCTCTGGGCTCCCTGGGTAGTA | 477 |
| TRIM32 | CCGCATAACCAGCTTGACCC | AGGGAGTGTACAGTGGCCAGG | 208 |
| CERKL | CCCTTTGCTCACTTTCTACCC | GGAACAGAAGGAAACTATCTCAA C | 459 |
| STL2 | GCTGTGTGAAAATCACTCTGTTC | TGCCAGACAAATCCAAAGAC | 584 |
| TREX1 | CGCGGGAGAGTGTGCAGC | GGTGGTGGAGGAACTGTGGGAG | 580 |
| BEST1 | CCTAGAACCATCAGCGCC | TCAAAGTAAGTTGGGGCCAG | 652 |
Figure 3Identification of a novel NRL mutation in this pedigree. Conventional sequencing profile around the position c.146 from the normal individual (III:5) and the affected individual (II:7).
Figure 4The amino acid sequences alignment of NRL in different species. The box indicates the P49 residue is highly conserved during the evolution. The symbol * is used to represent that this position is conserved, while the symbol: is used to represent the less conserved position.
Figure 5The p.P49L mutation in NRL increased its ability to transactivate Rho expression. WT or p.P49L mutant NRL expression constructs were co-transfected into HEK293 cells with pGL3-Rho-promoter and pRL-TK plasmids. The empty p3X-FLAG-CMV-7.1 expression vector was used as a negative control. The luciferase activities of whole cell lysates were measured. Data are the average of three replicate experiments and error bars show +/−1.00 SD. The asterisk indicates a significant difference.